InterMune Inc (ITMN)

ITMN (NASDAQ:Drugs)
$46.40
pos +0.00
+0.00%
Today's Range: 0.00 - 0.00 | ITMN Avg Daily Volume: 2,166,900
Last Update: 07/23/14 - 3:59 PM EDT
Volume: 0
YTD Performance: 215.00%
Open: $0.00
Previous Close: $46.40
52 Week Range: $10.95 - $47.72
Oustanding Shares: 98,883,136
Market Cap: 4,109,583,132
6-Month Chart
TheStreet Ratings Grade for ITMN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 8 8 8
Moderate Buy 0 0 0 0
Hold 2 2 3 3
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.64 1.64 1.75 1.75
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -17.10
Price Earnings Comparisons:
ITMN Sector Avg. S&P 500
-17.10 0.00 28.87
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
55.65% 256.65% 25.34%
GROWTH 12 Mo 3 Yr CAGR
Revenue 2.10 -0.46 -0.19
Net Income 0.00 0.59 0.00
EPS 0.00 -0.12 0.00
Earnings for ITMN:
EBITDA -0.19B
Revenue 0.03B
Average Earnings Estimates
Qtr (06/14) Qtr (09/14) FY (12/14) FY (12/15)
Average Estimate $-0.56 $-0.57 $-2.32 $-0.77
Number of Analysts 9 9 10 10
High Estimate $-0.52 $-0.52 $-2.18 $0.49
Low Estimate $-0.58 $-0.62 $-2.41 $-1.99
Prior Year $-0.78 $-0.62 $-2.72 $-2.32
Growth Rate (Year over Year) 28.63% 8.24% 14.85% 66.84%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Don't batten down the hatches yet.
Bullish
May 19, 2014 | 8:15 AM EDT
ITMN was upgraded from Market Perform to Outperform, Leerink Swann said. $41 price target. Company posted better clinical data in two t...
Bearish
Feb 28, 2014 | 8:09 AM EST
ITMN was downgraded from Outperform to Neutral, Credit Suisse said. Valuation call, based on a $33 price target. 
Bearish
Feb 26, 2014 | 7:57 AM EST
ITMN was downgraded from Outperform to Market Perform, Leerink Swann said. Valuation call, based on a $41 price target. 
InterMune, Novavax have promising products and acquisition possibilities.
Bullish
Jan 16, 2013 | 8:38 AM EST
ITMN was upgraded to Buy from Neutral, UBS said. $15 price target. Short term hurdles removed. 
Bearish
Aug 15, 2012 | 8:13 AM EDT
Shares of ITMN now seen reaching $8.50, UBS said. Estimates also lowered to reflect Esbriet pricing and sales. Neutral rating.

Columnist Conversations

The semiconductor sector performed poorly today with the Market Vectors Semiconductor (SMH) fund down over 2% ...
Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Before: Transparency is...
ive tried to sense how these new rules can possibly be good for the mkt--and struck out trying. the investmen...
Skip Raschke and I have been talking about THIS behind the scenes. Note the following excerpt: "The rules also...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.